Antagonist for Beta-Cell Survival: Novel Treatment For Type II Diabetes. (Hadasit)
- Summary
- Need:
There is a strong need for novel targeted based approaches for type II diabetes management.
Innovation:
We propose to develop selective antagonist for novel target to reduce beta-cell damage as a potential treatment for type 2 diabetes. We provide the first evidence of rescuing beta-cell death by blocking this target. The target is highly expressed in human pancreatic islets from T2D Patients. We have demonstrated that silencing of the target with siRNA rescued beta cells from Palmitate induced cell death.
- Technology Benefits
- This invention proposes a novel targeted therapy approach for the treatment of diabetes by modulating beta cell survival.
- Technology Application
- The application will aim at preserving the existing beta cell mass by preventing further beta cell death in a setting of Type II Diabetes.
- ID No.
- 8-2013-234
- Country/Region
- Israel
For more information, please click Here
